Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III melanoma

2014 ASCO Annual Meeting

30 May - 3 Jun 2014

Published: 2 Jun 2014

Views: 2326

Rating:

Save

Prof Alexander M. Eggermont, Erasmus University, Rotterdam, The Netherlands

At a press conference at ASCO 2014, Prof Eggermont talks about the initial efficacy and safety results from the EORTC 18071 phase III trial which looked at the use of ipilimumab versus placebo after complete resection of stage III melanoma.

Read the article for more.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for...

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )

Gynaecological cancer: New targets and immunotherapy developments

Dr Mark Shahin - Jefferson Health, Philadelphia, USA

Gynaecological cancer: New targets and immunotherapy developments ( Dr Mark Shahin - Jefferson Health, Philadelphia, USA )

The current status of multiple myeloma diagnosis and treatment

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

The current status of multiple myeloma diagnosis and treatment ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

Neoadjuvant immunotherapy improves outlook in high-risk melanoma ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )

An overview of treatment advances in gastric cancer

Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA

An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )

Locally and advanced immunotherapy developments and new agents in lung cancer

Dr George Simon - Moffitt Advent Health Clinical Research Unit, Tampa, USA

Locally and advanced immunotherapy developments and new agents in lung cancer ( Dr George Simon - Moffitt Advent Health Clinical Research Unit, Tampa, USA )

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard...

Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )

More from ecancer